VCEL Vericel Corporation

9.2
+0.7  (+8%)
Previous Close 8.5
Open 8.79
Price To Book 3.73
Market Cap 413,502,446
Shares 44,945,918
Volume 589,770
Short Ratio
Av. Daily Volume 736,715
Stock charts supplied by TradingView

NewsSee all news

  1. Vericel Provides Business and Financial Updates

    First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty Regarding Impact of COVID-19   CAMBRIDGE,

  2. Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance

    Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30am Eastern Standard Time

  3. Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020

    CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president

  4. Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020

    CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president

  5. Vericel to Report Fourth-Quarter 2019 Financial Results on February 25, 2020

    CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

BLA filing due mid-2020.
NexoBrid
Severe burns
Phase 2b topline data released March 2016. Full data released April 2016
ixmyelocel-T
Stem cells - Dilated Cardiomyopathy
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
MACI
Focal chondral cartilage defects in the knee.

Latest News

  1. Vericel Provides Business and Financial Updates

    First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty Regarding Impact of COVID-19   CAMBRIDGE,

  2. Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance

    Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at 8:30am Eastern Standard Time

  3. Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020

    CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president

  4. Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020

    CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president

  5. Vericel to Report Fourth-Quarter 2019 Financial Results on February 25, 2020

    CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and

  6. Vericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020

    CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO, will

  7. BARDA Initiates the Procurement of NexoBrid for Emergency Response

    YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ:VCEL) today announced that the U.S. Biomedical Advanced

  8. Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C.

  9. Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow

    Product Revenues of $30.5 Million Increase 36% Over Third Quarter 2018Full Year 2019 Revenue Guidance Raised to $116 to $118 MillionConference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE

  10. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  11. Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019

    CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo,

  12. Vericel to Present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019

    CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO &